Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR5 | P32302 | 1/20 | 1.00 |
| ▸ | APLNR | P35414 | 1/20 | 1.00 |
| ▸ | CCR6 | P51684 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 13/20 | 0.90 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.81 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.81 |
| ▸ | CRHBP | P24387 | 2/20 | 0.76 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.76 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Escin Ia SCHEMBL13007226 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 | |
| Escin Ia SCHEMBL13990760 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 | |
| Escin Ia SCHEMBL13007215 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 | |
| Escin Ia SCHEMBL18947797 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 | |
| Escin Ia SCHEMBL19361964 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 | |
| Escin Ib SCHEMBL23883543 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 | |
| Escin Ia SCHEMBL6246175 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 | |
| Escin Ib SCHEMBL15531983 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 | |
| Escin Ia SCHEMBL284871 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 | |
| Escin Ia SCHEMBL29434526 | 1.00 | CXCR5 (1.00) | CXCR5APLNRCCR6TOP1SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3210 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081346-A | Horse chestnut tiglyl coenzyme A ligase gene AcCCL, acCCL3 protein and application | — | 2026-05-26 | — | — | CN | claimed |
| CN-122031742-A | Starch film slow-release patch for promoting wound healing and preparation method thereof | 咸阳职业技术学院 | 2026-05-15 | — | — | CN | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| EP-4635501-A2 | SAPONIN DERIVATIVES WITH IMPROVED THERAPEUTIC WINDOW | Sapreme Technologies B.V. (NL) | 2025-10-22 | — | — | EP | claimed |
| EP-4631524-A2 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | Sapreme Technologies B.V. (NL) | 2025-10-15 | — | — | EP | claimed |
| EP-4611763-A1 | METHOD FOR PRODUCING NASAL FORMULATION COMPRISING AESCIN AND RUTIN | Mousavi Mirzaei, Seyed Mohammad (IR) | 2025-09-10 | — | — | EP | claimed |
| EP-4610278-A2 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | Sapreme Technologies B.V. (NL) | 2025-09-03 | — | — | EP | claimed |
| EP-4596052-A2 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | Sapreme Technologies B.V. (NL) | 2025-08-06 | — | — | EP | claimed |
| EP-4452331-B1 | TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERS | SAPREME TECH BV (NL) | 2025-08-06 | — | — | EP | claimed |
| EP-0493151-B1 | Slimming composition containing ginkgo biloba as alpha-2 blocker | OREAL (FR) | 1995-08-02 | — | — | EP | claimed |
| EP-0283713-B1 | COMPLEXES OF SAPONINS WITH PHOSPHOLIPIDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | INDENA S.p.A. (IT) | 1993-08-11 | — | — | EP | claimed |
| US-5118671-A | Antiinflammatory agent | INDENA S.P.A. (IT) | 1992-06-02 | — | — | US | claimed |
| EP-0231039-B1 | PROCESS FOR PREPARING IMMUNOLOGICAL COMPLEXES AND PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPLEXES | DE STAAT DER NEDERLANDEN VERTEGENWOORDIGD DOOR DE MINISTER VAN WELZIJN, VOLKSGEZONDHEID EN CULTUUR (NL) | 1992-01-08 | — | — | EP | claimed |
| EP-0109942-B1 | IMMUNOGENIC PROTEIN OR PEPTIDE COMPLEX, METHOD OF PRODUCING SAID COMPLEX AND THE USE THEREOF AS AN IMMUNE STIMULANT AND AS A VACCINE | Morein, Bror (SE) | 1991-03-06 | — | — | EP | claimed |
| CN-1048925-A | Producing with detection agent (the affinity thing of cholesterol) and visual developer serves as that the basis is used for method and this application of compound at the affinity enzyme compound of the visual demonstration cholesterol of patient skin surface | NII FIZ KHIM MEDITSINY (SU) | 1991-01-30 | — | — | CN | claimed |
| EP-0338189-A2 | Method of producing affin-enzymatic compounds, for the visual detection of cholesterol on the surface of the skin of a patient, based on a detecting agent with an affinity for cholesterol and a visualisation agent | 2860601 Canada Inc. (CN) | 1989-10-25 | — | — | EP | claimed |
| EP-0180564-A2 | Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents | Morein, Bror (SE) | 1986-05-07 | — | — | EP | claimed |
| EP-0109942-A2 | Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine | Morein, Bror (SE) | 1984-05-30 | — | — | EP | claimed |
| US-4101652-A | Pharmaceutically active complexes and pharmaceutical compositions containing eascin and sterols | INVERNI DELLA BEFFA S.P.A. (IT) | 1978-07-18 | — | — | US | claimed |